• 廣西醫(yī)科大學(xué)一附院普外科(南寧530021);

運用S-P免疫組化法對30例手術(shù)治療的男性肝細(xì)胞癌(HCC)患者癌組織、癌周組織及20例良性病變肝組織的雄激素受體(AR)、雌激素受體(ER)以及孕激素受體(PR)進(jìn)行了檢測。結(jié)果:肝癌組織AR陽性率為80.0%,顯著高于癌周組織(46.7%)及良性病變肝組織(40.0%),P<0.01,后兩者比較無顯著性差異(P>0.05);癌組織ER陽性率為43.3%,顯著低于癌周組織(80.0%),P<0.01,與良性病變肝組織(50.0%)比較無差異(P>0.05);PR陽性率在3種組織中比較無顯著性差異(P>0.05)。本實驗結(jié)果提示:性激素通過其受體介導(dǎo)在HCC的發(fā)生、發(fā)展中起一定作用;測定癌組織性激素受體狀態(tài)可對肝癌患者預(yù)后進(jìn)行評估,因此,AR及ER狀態(tài)可作為其預(yù)后判斷指標(biāo)。

引用本文: 肖開銀,李紹森,盧全書. 性激素受體在肝細(xì)胞癌的表達(dá)及其臨床意義. 中國普外基礎(chǔ)與臨床雜志, 1999, 6(2): 96-97. doi: 復(fù)制

版權(quán)信息: ?四川大學(xué)華西醫(yī)院華西期刊社《中國普外基礎(chǔ)與臨床雜志》版權(quán)所有,未經(jīng)授權(quán)不得轉(zhuǎn)載、改編

1. 李永國, 楊竹林, 云正芬等. 性激素和凝集素受體在膽囊癌組織中的表達(dá)及意義. 臨床肝膽病雜志, 1994; 10(1)∶25.
2. Lqbal M, Wilkin P, Johnson M, et al. Sex steroid receptor proteins in fetal, adult and malignant human liver tissue. Br J Cancer, 1983; 48(6)∶791.
3. Nagasue N, Ito A, Yakaya H, et al. Androgen and estrogen receptors in hepatocellular carcinoma and surounding parenchyma. Gastroentrology, 1985; 89(3)∶643.
4. Nagasue N, Kohno H, Chang YC, et al. Androgen and estrogen receptors in hepatocellular carcinoma and the surounding liver in women. Cancer, 1989; 63(1)∶112.
5. 濱崎啟介. 肝癌患者雌激素和雄激素受體研究. 國外醫(yī)學(xué)腫瘤學(xué)分冊, 1989; 16(3)∶175.
6. Nagasue N, Yakaya H, Chang YC, et al. Active uptake of testosterone by androgen receptor of hepatocellular carcinoma in human. Cancer, 1986; 57(1)∶2162.
7. 顧公望. 性激素與肝臟腫瘤. 國外醫(yī)學(xué)腫瘤學(xué)分冊, 1987; 14(6)∶324.
8. Yu L, Nagasue N, Makino Y, et al. Effect of androgens and their manipulation on cell growth and androgen receptor levels in ARpostive and negative human hepatocellular carcinoma. J Hepatol, 1995; 22(3)∶295.
9. Nagasue N, Chang YC, Hayashi T, et al. Androgen receptor in hepatocellular carcinoma as a prognostic factor after hepatic resectioin. Ann Surg, 1989; 209(4)∶424.
  1. 1. 李永國, 楊竹林, 云正芬等. 性激素和凝集素受體在膽囊癌組織中的表達(dá)及意義. 臨床肝膽病雜志, 1994; 10(1)∶25.
  2. 2. Lqbal M, Wilkin P, Johnson M, et al. Sex steroid receptor proteins in fetal, adult and malignant human liver tissue. Br J Cancer, 1983; 48(6)∶791.
  3. 3. Nagasue N, Ito A, Yakaya H, et al. Androgen and estrogen receptors in hepatocellular carcinoma and surounding parenchyma. Gastroentrology, 1985; 89(3)∶643.
  4. 4. Nagasue N, Kohno H, Chang YC, et al. Androgen and estrogen receptors in hepatocellular carcinoma and the surounding liver in women. Cancer, 1989; 63(1)∶112.
  5. 5. 濱崎啟介. 肝癌患者雌激素和雄激素受體研究. 國外醫(yī)學(xué)腫瘤學(xué)分冊, 1989; 16(3)∶175.
  6. 6. Nagasue N, Yakaya H, Chang YC, et al. Active uptake of testosterone by androgen receptor of hepatocellular carcinoma in human. Cancer, 1986; 57(1)∶2162.
  7. 7. 顧公望. 性激素與肝臟腫瘤. 國外醫(yī)學(xué)腫瘤學(xué)分冊, 1987; 14(6)∶324.
  8. 8. Yu L, Nagasue N, Makino Y, et al. Effect of androgens and their manipulation on cell growth and androgen receptor levels in ARpostive and negative human hepatocellular carcinoma. J Hepatol, 1995; 22(3)∶295.
  9. 9. Nagasue N, Chang YC, Hayashi T, et al. Androgen receptor in hepatocellular carcinoma as a prognostic factor after hepatic resectioin. Ann Surg, 1989; 209(4)∶424.